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Recent remarkable progress in the fields of cancer genomics, computational analysis and drug discovery have changed the
whole paradigm in cancer research. So called precision oncology, defined as molecular profiling of tumors to identify druggable
alterations, is rapidly developing and waiting for entering the mainstream of cancer research as well as practice [1]. In the era
of precision oncology, traditional classification based on organ or pathology do not have clinical meaning anymore. Molecular
subtype base on next-generation sequencing (NGS) will lead us to appropriate molecular targeted agents. 
Head and neck squamous cell carcinoma (HNSCC) is not a specific disease entity, but rather a broad category of diverse
tumor types arising from various anatomic structures including oral cavity, oropharynx, hypopharynx, larynx and paranasal
sinus. HNSCC is highly heterogeneous group of disease arises from the mucosal lining of the upper aerodigestive tract, demon-
strates squamous differentiation, and involves older men with a long history of smoking. The prognosis by anatomic subsite
quite differ. Human papilloma virus positive oropharyngeal cancer showed very good prognosis while oral cavity cancer had
worst prognosis. In the era of NGS, HNSCC become more heterogeneous by mutational status [2-4]. 
Traditional design of clinical trials has faced big challenge for these heterogeneity and rarity. One solution is umbrella trial.
In an umbrella trial, patients with specified cancer type are centrally screened and assigned to one of several molecularly
defined subtrials where they receive matched targeted agents [5]. Some novel umbrella trials such as BATTLE trial [6] or
MOSCATO trial [7] suggest that such a biomarker driven clinical trial can give appropriate benefit to the patients. To perform
an umbrella trial, precise NGS based molecular phenotyping should be practical and working in the level of clinic. To date,
there was surprisingly few study deals with the feasibility of molecular phenotyping for umbrella trial. We should answer the
questions whether precision oncology is just a theory or whether it is realistically feasible. We should answer how we implement
the precision oncology into the clinic and prove the patients’ benefit.
In this issue of Cancer Research and Treatment, Lim et al. [8] reported the feasibility of targeted NGS to guide the treatment of
HNSCC. The authors tested the feasibility from tissue sample process to analysis of NGS and mRNA expression at the practical
level. Mutation profiles were similar with prior reports [2-4] and the authors found several targetable alterations such as
PIK3CA, CDKN2A and CCND1.
Based on this success, KCSG (Korean Cancer Study Group) Head and Neck Cancer and Esophageal Cancer Committee
launched novel umbrella trial: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH, NCT
03292250), which is the first umbrella trial for HNSCC in the world. TRIUMPH trial is for recurred/metastatic HNSCC, con-
sisting of 5 targeted therapies including phosphoinositide 3-kinase inhibitor BYL719, pan-HER inhibitor poziotinib, fibroblast
growth factor receptor inhibitor nintedanib, CDK4/6 inhibitor abemaciclib, andd immune checkpoint inhibitor durvalumab+/–
tremelimumab. TRIUMPH trial is investigator-initiated trial, and Korean Cancer Study Group affiliated 37 institutes participate.
We think TRIUMPH trial is one small step for head and neck cancer, but hope to be one giant leap for precision oncology in
HNSCC. 
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